Breaking Finance News

Sarepta Therapeutics (NASDAQ:SRPT) has been upgraded from Underperform to Hold in a report by Jefferies earlier today.

Just yesterday Sarepta Therapeutics (NASDAQ:SRPT) traded 91.30% higher at $28.15. SRPT’s 50-day average is $26.16 and its two hundred day moving average is $20.47. With the last stock close up 163.13% from the two hundred day average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same time period. 29,541,278 shares of Sarepta Therapeutics exchanged hands, up from ann average trading volume of 2,328,380.

Jefferies has upgraded Sarepta Therapeutics(NASDAQ:SRPT) from Underperform to Hold in a statement released 9/19/2016.

On 7/22/2016, Needham released a statement on Sarepta Therapeutics(NASDAQ:SRPT) raised the target price from $20.00 to $26.00 that suggested an upside of 0.15%.

See Graphic Below:

Sarepta Therapeutics (NASDAQ:SRPT)

A total of 13 equity analysts have released a research note on Sarepta Therapeutics. Three firms rate the stock a strong buy, one firm rate the stock a buy, five firms rate the company a hold, four firms rate the company to underperform, and finally one firmrate the stock as sell with a one year target of $20.77

Sarepta Therapeutics has a one-year low of $8.00 and a one-year high of $56.18. SRPT’s total market value is currently $0.0.

About Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, and is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *